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The development of a clean procedure for the preparation of
heterocyclic compounds is a major challenge in modern het-
erocyclic chemistry in view of the environmental, practical
and economic issues. Pyrazolines are an important class of het-
erocyclic compounds containing two nitrogen atoms in the ﬁve
membered ring. The substituted 2-pyrazolines have found
application as activators for polymerization (Bauer and
Piatert, 1981), dyes for wool, nylon (Evans and Waters,
554 M. Yusuf, P. Jain1978), as electro photographic conductors (Murayama and
Mater, 1981) and as wavelength shifters in liquid and
polymer scintillation (Poduzhailo et al., 1979). Pyrazoline
derivatives are the electron rich nitrogen heterocycles which
play an important role in the diverse biological activities.
These heterocyclic compounds widely occur in nature in the
form of alkaloids, vitamins, pigments and as constituents of
plant and animal cell. Considerable attention has been
focused on the pyrazolines and substituted pyrazolines due
to their interesting biological activities. These compounds
have been found to possess anti-fungal (Korgaokar et al.,
1996), anti-depressant, anticonvulsant (Palaska et al., 2001;
Rajendra et al., 2005; Ozdemir et al., 2007; Ruhogluo et al.,
2005), anti-inﬂammatory (Udupi et al., 1998), anti-bacterial
(Nauduri and Reddy, 1998) and anti-tumor (Taylor and
Patel, 1992) properties. The pyrazole moiety is found in
blockbuster drugs such as celecobix (Penning et al., 1997),
sildenaﬁl (Terrett et al., 1996) and rimonabant (Seltzmann
et al., 1995). Recently a very important review has been
published upon the studies of pyrazoline compounds (Kumar
et al., 2009).
2. Discussion
1,3,5-Triaryl-2-pyrazolines 3 (Li et al., 2007) have been
prepared through the reaction of chalcones and phenyl
hydrazine hydrochloride (Scheme 1) in the presence of
sodium acetate-acetic acid aqueous solution under
ultrasound irradiation.
3,4,5-Metalated pyrazoles 6 and 7 were synthesized
(Gonzalez-Nogal et al., 2007) by 1,3-dipolar cycloadditions
of silyl, disilyl, and silylstannylacetylenes with N-
phenylsydnone or trimethylsilyldiazomethane (Scheme 2).
The heterocyclics 5-(-4-(Substituted)phenyl)-3-(4-hydroxy-
3-methylphenyl)-4,5-dihydro-1H-1-pyrazolyl-2-toluidinome-
thane thione 12 and 5-(substituted) phenyl-3-(4-hydroxy-3-Ar1
O
Ar2 +
NHNH2.HC
C
a) Ar1=C6H5, Ar2=4-CH3OC6H4 b) Ar1=C6H5, 4-CH3C6H4 c) Ar1=C6H5, Ar2=C6
Ar2=2-ClC6H4, g) Ar1=C6H5, Ar2=3-BrC6H4, h) Ar1=C6H5, Ar2=4-O2NC6H4, i) A
21
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Schememethylphenyl)-4,5-dihydro-1H-1-pyrazolyl-2-methoxyanilino
methane thione 13 were obtained (Ali et al., 2007) by the
reaction between hydrazine hydrate and chalcones 10
followed by condensation with the appropriate aryl
isothiocyanate (Scheme 3).
Synthesis of 5-substituted-3-dimethoxyphosphono-pyra-
zoles 16 and 17 and 2-pyrazolines 20 and 21 has been accom-
plished (Conti et al., 2007) through 1,3-dipolar cycloaddition
of a suitable nitrile imine to monosubstituted alkynes 15 and
alkenes 19 as shown in Scheme 4.
An interesting method ha been reported by Alexander V.
Shevtson et al. (2007) for the synthesis of 1-mono- and 1,2-
diacylpyrazolidines 23 as well as 1-arylsulfonyl-2-pyrazolines
24 which is described in Scheme 5.
The compounds 1-(2,4-dinitrophenyl)-3-(3-nitrophenyl)-5-
(4-substituted phenyl)-2-pyrazolin-4-ones 30 have been
prepared by the oxidation of 1-(2,4-dinitrophenyl)-3-(3-nitro-
phenyl)-5-(4-substitutedphenyl)-4-bromo-2-pyrazolines 29
with dimethylsulfoxide (Mishra et al., 2007). The later has
been released via the reactions sequence which is depicted in
Scheme 6.
An efﬁcient method (Joshi et al., 2008) has been reported
regarding the synthesis of 5-substituted-2-thiol-1,3,4-
oxadiazoles 32 according to the protocol as shown in
Scheme 7.
Braulio Insuasty et al. Insuasty et al. (2008) have
synthesized new bis-3,5-diphenylpyrazolines 36 from the
cyclization of bischalcones 35 with hydrazine hydrate in
acetic acid medium. The later was prepared by the Claisen–
Schmidt reaction of bis-acetophenone 35 with suitable
aromatic aldehydes (Scheme 8).
Some biologically signiﬁcant bis-heterocycles (Jayashankra
and Lokanatha, 2008) bearing pyrazoline moieties 40
have been synthesized starting from pyrazolyl aldehyde
37 through the reaction sequence as described in
Scheme 9.l
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Synthetic and biological studies of pyrazolines and related heterocyclic compounds 5553,5-Diaryl carbothioamide pyrazolines 44–46 designed
as mycobactin analogs (mycobacterial siderophore) were
reported to be potent antitubercular agents under iron limiting
condition (Jayaprakash et al., 2008). These compounds were
obtained via the usual protocol as given in Scheme 10.
1,3,5-Trisubstituted pyrazolines 47 have been oxidized to
the corresponding pyrazoles 48 in high yield with tris(4-bromo-
phenyl)aminium (TBPA) hexachloroantimonate in chloroform
at room temperature (Gang et al., 2008) (Scheme 11).A number of 1,3-diaryl-5-(cyano-,aminocarbonyl-andeth-
oxycarbonyl-)-2-pyrazoline, pyrrolo[3,4-c]pyrazole-4,6-dione
and 1,3,4,5-tetraaryl-2-pyrazoline derivatives 52 were prepared
(Abunada et al., 2008) by the reaction of nitrilimine with
different dipolarophilic reagents (Scheme 12).
Recently the Michael accepters (Padmavathi et al., 2008),
1-arylsulfonyl-2-styrylsulfonylethenes 53 have been used as
synthons to develop bis-pyrroles 55, pyrrolyl pyrazolines 56
and pyrrolyl isoxazolines 57 by 1,3-dipolar cycloaddition of
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556 M. Yusuf, P. Jaintosylmethyl isocyanide, nitrile imines and nitrile oxides
(Scheme 13).
A facile, InCl3 and/or DABCO mediated synthesis
(Krishna et al., 2008) of 3,5-disubstituted pyrazolines 61 and
pyrazoles 63 and 66 has been achieved by 1,3-dipolar
cycloaddition of ethyl diazoacetate (EDA) with various
activated oleﬁns 60 under solvent-free conditions at ambient
temperature (Schemes 14 and 15).
A series of pyrazoline derivatives 69 were designed and pre-
pared (Zhao et al., 2008) by introducing methoxyacrylate
pharmacophore into the scaffold of 1-acetyl-3,5-diarylpyrazo-
line 68 according to the method which is shown in Scheme 16.
The synthesis of aryl-substituted pyrazolines 73 has been
developed by Matthias Beller and co-workers (Alex et al.,
2008) in which phenylhydrazine reacts with 3-butynol 71 in
the presence of a catalytic amount of zinc triﬂate to give
pyrazoline derivatives through the involvement of hydrazone
72 (Scheme 17).
A series of 1-arylmethyl-3-aryl-1H-pyrazole-5-carbohyd-
razide hydrazone derivatives 75 were synthesized by
Bao-Xiang Zhao et al. Xia et al. (2008) (Scheme 18) and the
effects of all the compounds on A549 cell growth have
also been investigated. The results showed that all
compounds had almost inhibitory effects on the growth ofA549 cells. The study on structure activity relationships and
prediction of lipophilicities of compounds showed that
compounds with Log P values in the range of 4.12–6.80 had
inhibitory effects on the growth of A549 cell and the
hydrazones derived from salicylaldehyde had much more
inhibitory effects.
The analgesic and anti-inﬂammatory properties of novel 3/
4-substituted-5-triﬂuoromethyl-5-hydroxy-4,5-dihydro-1H-1-
carboxyamidepyrazoles 77 (where 3/4-substituent are H/H,
Me/H, Et/H, Pr/H, i-Pr/H, Bu/H, t-Bu/H, Ph/H, 4-Br-Ph/H
and H/Me) were determined (Sauzem et al., 2008) and these
compounds were synthesized in the exploration of the
bioisosteric replacement of benzene present in salicylamide
with a 5-triﬂuoromethyl-4,5-dihydro-1H-pyrazole scaffold
(Scheme 19).
A series of N1-propanoyl-3,5-diphenyl-4,5-dihydro-(1H)-
pyrazole derivatives 81 were synthesized (Chimenti et al.,
2008) from the usual reaction of chalcone 80 with hydrazine
hydrate (Scheme 20).
The cyclocondensation reaction (Almeida da Silva et al.,
2008) of 4-methoxy-1,1,1-triﬂuoro[chloro]-4-(substituted)-
alk-3-en-2-ones 82 and isoniazid (INH) led to the formation
of 3-substituted 5-hydroxy-5-triﬂuoro[chloro]methyl-1H-1-
isonicotinoyl-4,5-dihydropyrazole 83 (Scheme 21).
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Synthetic and biological studies of pyrazolines and related heterocyclic compounds 557One pot and regioselective synthesis (Bonacorso et al.,
2009) of a novel series of 3-aryl(heteroaryl)-5-triﬂourometh-
yl-5-hydroxy-4,5-dihydro-1H-pyrazolyl-carbohydrazides 86
and bis-(3-aryl-5-triﬂouromethyl-5-hydroxy-4,5-dihydro-1H-
pyrazol-1-yl)methanones 87 have been reported from the
reactions of 4-alkoxy-4-aryl(heteroaryl)-1,1,1-triﬂouro-3-en-2-ones 85 under the reaction conditions which are shown in
Scheme 22.
Eva Frank et al. (2009) have investigated a highly
diastereoselective Lewis acid induced intramolecular 1,3-
dipolar cycloadditions of alkenyl phenylhydrazones 90
(containing various substituents on the aromatic ring) under
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558 M. Yusuf, P. Jainfairly mild conditions to furnish andros-5-ene-fused
arylpyrazolines 93 in good to excellent yields (Scheme 23).
The compounds 100 and 101 have been prepared from the
cyclization of chalcone 99 with hydrazine hydrate and guani-
dine respectively (Solankee et al., 2009). The compounds 99
were released from the condensation of ketone 98 with
suitable substituted aromatic/heterocyclic aldehydes under
alkaline conditions. The compound 98 was obtained via two
step reaction starting from 96 as shown in Scheme 24.
The cyclization reaction (Zsoldos-Mady et al., 2009) of 1-
phenyl-3-ferrocenyl-2-propen-1-one 102 with substitutedhydrazines led to the formation of pyrazolines 103–107.
The nature of substitutent on the hydrazine moiety had
profound effect upon the products distribution in these
reaction. The reaction with methylhydrazine could provide
two regioisomeric pairs of pyrazolines 104, 105 and 107 and
pyrazoles 103 and 106 (Scheme 25).
The compound 1,2 pyrazolines 113 have been prepared
(Gowramma et al., 2009) because of the interesting
pharmacological properties associated to these substrates
(Scheme 26). The synthesized compounds were screened for
their anti-cancerous activity. It was found that 1-(bis-N,N-
(chloroethyl)-amino acetyl) 3,5-disubstituted-1,2-pyrazoline
showed anticancer activity.
A variety of bis(3-aryl-4,5-dihydro-1H-pyrazole-1-thiocarb-
oxamides) 115 and bis(3-aryl-4,5-dihydro-1H-pyrazole-
1-carboxamides) 116 were prepared (Barsoum and Girgis,
2009) via the reaction of bis(2-propen-1-ones) 114
with thiosemicarbazide/KOH and semicarbazide/AcOH
respectively (Scheme 27).
Novel series of 1-(2,4-dimethoxy-phenyl)-3-(1,3-diphenyl-
1H-pyrazol-4-yl) propenone 119 had been prepared (Bandgar
et al., 2009) by the Claisen–Schmidt condensation of 1-(2,4-
dimethoxy-phenyl)ethanone 117 and substituted 1,3-diphe-
nyl-1H-pyrazole-4-carbaldehydes 118 (Scheme 28). The later
compounds were obtained by the Vilsmeir–Haack reaction of
acetophenone phenylhydrazones.
1-Aryl-4,4-dichlorobut-3-en-1-ones 123 were efﬁciently syn-
thesized (Guirado et al., 2009) by the treatment of acetophe-
nones with anhydrous chloral, followed by dehydration and
reductive dechlorination (Scheme 29). The compounds 122
reacted with hydrazine hydrate and methylhydrazine to give
127 and 128 respectively in high to quantitative yields.
Mohamed Abdel-Aziz et al. (Shoman et al., 2009) have
reported the synthesis of 3,5-diaryl-2-pyrazoline derivatives
132 which were obtained via the reaction of various
chalcones 131 with hydrazine hydrate in ethanol. The
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560 M. Yusuf, P. Jaincompounds 132 were further converted to various N-
substituted derivatives 133–138 according to the reaction
conditions and protocol as given in Scheme 30.
Effective syntheses of endo- and exocyclic a,b-unsaturated
ketones as C‚C dipolarophiles (Mernyak et al., 2009) were
carried out in the estrone series. 1,3-dipolar cycloadditions ofunsaturated ketones of estrone 3-methyl and 3-benzyl ether
with nitrilimines stereoselectively furnished two regioisomers
of new condensed pyrazolines 140 and 141 in a ratio of 2:1
(Scheme 31).
The reaction (Khode et al., 2009) of various substituted 3-
aryl-1-(3-coumarinyl)propan-1-ones 147 with phenylhydrazine
in the presence of pyridine led to the synthesis of 5-
(substituted)aryl-3-(3-coumarinyl)-1-phenyl-2-pyrazolines 148
(Scheme 32).
1-[(Benzoxazole/benzimidazole-2-yl)thioacetyl]pyrazoline
derivatives 154 were obtained (Kaplancikli et al., 2009) by
reacting 3,5-diaryl-1-(2-chloroacetyl)pyrazolines 153 with 2-
marcaptobenzoxazole/benzimidazole. The later compounds
were released starting from benzaldehydes 149 and 150
according to the reactions sequence which are depicted in
Scheme 33.
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Synthetic and biological studies of pyrazolines and related heterocyclic compounds 561Recently, N1-acetyl-5-aryl-3-(substituted styryl)pyrazolines
158 have been prepared (Pathak et al., 2009) from the cyclo-
condensation of 1,5-substituted diphenyl-1,4-pentadien-3-
ones 157 with hydrazine hydrate and a cyclizing agent such
as acetic acid in ethanol (Scheme 34).
Tricyclic fused pyrazolines 160 have been synthesized
(Scheme 35) from the reaction of 3-arylidenechromanones/thi-
ochromones 159 with (4-carboxyphenyl)hydrazine in hot
anhydrous pyridine solution (Levai and Jeko, 2009).
The oxidation of 1,3,5-trisubstituted 4,5-dihydro-1H-pyra-
zoles 161 to the corresponding pyrazoles 162 has been achieved
by utilizing tetrabromine-1,3,5,7-tetrazatricyclo[3.3.1.1]decane
complex, Br4-TATCD, in glacial acetic acid under microwave
irradiation and conventional thermal condition (Scheme 36)
at room temperature with excellent yields (Azarifar and
Khosravi, 2009).The reaction (Singh et al., 2009) of dibenzalacetone 165
with hydrazine hydrate and formic acid yielded a novel
2-pyrazoline 166 (Scheme 37).
The reaction of cholest-5-en-7-one 167 with thiosemicarba-
zide in sodium ethoxide (Scheme 38) afforded 20-thiocarba-
moyl-cholest [5,7-cd] pyrazoline 168, [X=H] 20-
thiocarbamoyl-3b-acetoxycholest [X=OAc] pyrazoline 168,
and 20-thiocarbamoyl-3b-chloro cholest pyrazoline [X=Cl]
168 respectively (Shamsuzzaman Khan and Alam, 2009).
The synthesis of pyrazolines 170 was carried out to study
the effect of bromine on the biological activity (Kumar
et al., 2009). These compounds were brominated by using
bromine in acetic acid (Scheme 39). All synthesized
compounds were tested for antimicrobial activity against
gram positive and gram negative bacteria. It was found that
most of the compounds were found active against all
bacteria except Escherichia coli.
The substituted carboxylic acid hydrazides 171 reacted with
ethenetetracarbonitril in dimethyl formamide (Scheme 40) with
the formation of diacylhydrazines 172 and 5-amino-1-substiut-
ed pyrazole-3,3,4-tricarbonitriles 173 (Abdel-Aziz et al., 2009).
A new series of 1H-3-(40-substituted phenyl)-5-(600-methoxy
napthaline)-2-pyrazolines 179 and 1H-3-(40-substituted phe-
nyl)-5-(600-methoxy napthaline)-2-isoxazolines 178 have been
synthesized (Jadhav et al., 2009) from the reaction of 1-(40-
substituted phenyl)-3-(600-methoxynapthaline)-2-propene-1-
one 177 with hydrazine hydrate and hydroxylamine
hydrochloride respectively (Scheme 41).
The enaminonitrile 181 was used as the key intermediate for
the synthesis of polyfunctionally substituted heterocycles pyr-
azoles 184 (Scheme 42) incorporating benzothiazole 183 moi-
ety via its reactions with some N-nucleophiles (Bondock
et al., 2009).
Recently Sheena Shashikanth et al Rai et al. (2009) have
reported the synthesis of a series of novel 2-[1-(5-chloro-2-meth-
oxy-phenyl)-5-methyl-1H-pyrazol-4-yl]-5-(substituted-phenyl)-
[1,3,4]oxadiazoles 189 from cyclization of substituted benzoic
acid N-[1-(5-chloro-2-methoxy-phenyl)-5-methyl-1H-pyra-
zole-4-carbonyl]-hydrazide 188 with phosphorousoxychloride
(Scheme 43).
A new class of heterocycles, substituted pyrazoles 193, isox-
azoles 192, pyrimidines 194, thioxopyrimidines 195 were
released from the Michael adducts 190, 2-(1,2-diaroylethyl)
malononitrile and 2-(1,2-diarylsulfonylethyl) malononitrile
(Padmaja et al., 2009) which subsequently underwent cyclo-
condensation with the appropriate nucleophiles to produce
the ﬁnal compounds (Scheme 44).
The compounds 1-(4-methylcoumarinyl-7-oxyacetyl)-3,5-
dimethyl-4(arylazo)pyrazoles 198 and 1-(4-methylcoumarinyl-
7-oxyacetyl)-3-methyl-4-(substituted phenyl) hydrazono-2-pyr-
azolin-5-ones 199 were prepared (Manojkumar et al., 2009)
according to the protocol which is described in Scheme 45.
The thiocarbamoyl derivative 200 was reacted with hydra-
zine hydrate (Fadda et al., 2009) to afford the pyrazole
derivatives 201 (Scheme 46).
A new series of chalcones 205 were synthesized (Revana-
siddappa et al., 2010) from the condensation of simple
aldehydes with substituted acetophenones under alkaline
medium (Scheme 47). The cyclization reaction of chalcones
with 206 in the presence of glacial acetic acid provided 207.
a-Pyranochalcones 208 and pyrazoline derivatives 210 and
214 were prepared (Warane et al., 2010) to discover chemically
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Synthetic and biological studies of pyrazolines and related heterocyclic compounds 563diverse anti malarial leads (Schemes 48 and 49). This is the ﬁrst
instance wherein chromeno-pyrazolines have been found to be
active antimalarial agents.3,5-Diaryl pyrazolines analogs 217 were synthesized
(Karuppasamy et al., 2010) from the reaction of 215 with
hydrazine hydrate and evaluated for their monoamine
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Synthetic and biological studies of pyrazolines and related heterocyclic compounds 565oxidase (MAO) inhibitory activity (Scheme 50). These
compounds were found reversible and selective toward
MAO-A with selective index in the magnitude of 103–105.New pyrazolines derivatives 223 and 224 have been syn-
thesized (Hussain and Sharma, 2010) according to the
protocol as given in Scheme 51. In order to introduce
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Synthetic and biological studies of pyrazolines and related heterocyclic compounds 567methyl group at C-16 instead of C-13, dehydocestus lactone
was allowed to react with an ethereal solution of diazoethane.
The synthesis (Sahoo et al., 2010) of novel 3,5-diaryl
pyrazolines 226–230 have been investigated in order to studyCHO +
CH3 CH3
O
NaOH/ EtOH
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Scheme 3their monoamine oxidase (MAO) inhibitory property
(Scheme 52). All the molecules were found to be reversible
and selective inhibitor for either one of the isoform (MAO-A
or MAO-B).
A series of 1,3,5-trisubstituted pyrazolines 234 were synthe-
sized (Scheme 53) and evaluated for in vitro antimalarial
efﬁcacy against chloroquine sensitive (MRC-02) as well as
chloroquine resistant (RKL9) strains of Plasmodium falcipa-
rum (Achraya et al., 2010). Some of the compounds showed
better antimalarial activity than chloroquine against resistant
strain of P. falciparum and were also found active in in vivo
experiment.
The reaction of pregnenolone 235 with substituted benzal-
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568 M. Yusuf, P. Jainthe corresponding benzylidine derivatives 236 and ﬁnally the
reaction of the later with hydrazine hydrate provided
pyrazoline 237 as the ﬁnal product (Scheme 54).
Novel pyrazolines 242 and 245 were synthesized (Chen
et al., 2010) from the cyclization of chalcone 240 and 243
with hydrazines 241 and 244 respectively according to the
protocol as given in the Scheme 55.Chalcones 248 were prepared from substituted acetoph-
enones and substituted benzaldehydes (Scheme 56) and
condensed with hydrazine hydrate (Venkataraman et al.,
2010) in methanol to yield the corresponding pyrazolines
249.
Some new pyrazoline derivatives 254 were synthesized
(Ramesh and Sumuna, 2010) by reacting chalcones 252 of
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Synthetic and biological studies of pyrazolines and related heterocyclic compounds 5692-acetyl thiophene 250 with phenyl hydrazine hydrochloride in
the presence of alcohol and pyridine (Scheme 57).
An efﬁcient method has been established for the synthesis
(Kasabe and Kasabe, 2010) of new pyrazoline derivatives
260 which were obtained from the reaction of chalcone 259
with thiosemicarbazide under alkaline alcoholic condition.
The intermediate 259 was released from the reaction
sequence as shown in Scheme 58.
The synthesis (Gembus et al., 2010) of biologically impor-
tant 3,4-substituted pyrazolines 263 has been achieved by anorganocatalyzed aza-Michael/transimination domino reaction
between hydrazones and enones 262 making use of a mixture
of heterogeneous resin-bound acid/base reagents (Scheme 59).
A series of new succinyl spacer bis-(3,5-substituted 2-pyraz-
olines and 1H-pyrazoles) and the non-symmetrical 2-pyrazo-
lines derivatives had been synthesized (Bonacorso et al., 2010).
The succinyl substituted bispyrazoles 266 were obtained from
the cyclocondensation reactions of 4-substituted 4-alkoxy-
1,1,1-trihaloalk-3-en-2-ones 264 (where the 4-substituents are
H, Me, Ph, 4-FC6H4, 4-ClC6H4, 4-OMeC6H4, 4-NO2C6H4,
NH2
NH
O
O
O
CH3
O
N N
N
N O
CH3
CH3
O
O O
CH3
R
NH N
N
N O
O
CH3
O
O O
CH3
R
N N O
CH3
O CH3
R
N N O
CH3
O O CH3
R
AcOH
AcOH
197
198
199
Scheme 45
Ph
HNPh SH
CH3
O O
+ NH2NH2
Ph
HNPh NHNH2
CH3
O O
N
N
H
CH3Ph
O
HNPh
EtOH
TEA
200
201
202
Scheme 46
OHC CH3CO
+
R R'
N
CONHNH2
N N
O
N
R R'
AcOH
NaOH/ EtOH
203 204
205
206
207
CH=CHCO
R R'
Scheme 47
570 M. Yusuf, P. Jain
O O
NN CH3
O
O
O
CH3
CH3
O O
O
O
CH3
CH3
O
O O
NN
O
O
CH3
CH3
Gc
210
Ga3
Reagents and conditions a) NH2NH2.H2O, AcOH; b) MeOH, PhNHNH2, AcOH
a
b
208
209
Scheme 48
OH
CH3
O
+
F
O
H
OH
O
F
OH
N
F
N CH3
O
Reagents and Conditions a) NaOH/ MeOH, rt  b) NH2NH2.H2O/ AcOH
a
b211 212
213
214
Scheme 49
OH X
O
OH
N N
H
X
OH
N N
X
NH
S
R
NH2NH2.H2O, EtOH,reflux R-C6H4-NCS, MeOH
215
216
217
Scheme 50
Synthetic and biological studies of pyrazolines and related heterocyclic compounds 5711-naphthyl and 2-furyl) with succinic acid dihydrazide in
ethanol as solvent under the controlled reaction conditions
(Scheme 60).
The complexes of 2-(8-quinolinol-5-yl)-amino methyl-3(4-
methyl phenyl)-5-(phenyl)-pyrazoline 272 with Cu(II), Mn(II)and Zn(II) have been synthesized (Patel et al., 2010)
according to the method which is described in Scheme 61.
Recently, B. Vibhute et al. Mokle et al. (2010) have pre-
pared a series of 2-pyrazolines 274 from the cyclization
reaction of a,b-unsaturated ketone 273 with hydrazine
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572 M. Yusuf, P. Jainhydrate/phenyl hydrazine using triethanolamine as the solvent
(Scheme 62).
New pyrazolines 278 were synthesized starting from the
condensation of substituted aldehydes with substituted ace-
tophenones in the presence of alkali to yield chalcones 277.
The resulted chalcones were further reacted with phenyl hydra-
zine hydrochloride in ethanol and pyridine (Das et al., 2010) to
provide 278 as the ﬁnal products (Scheme 63).
New pyrazolines have been obtained from the condensation
of chalcones of 41-piperazine acetophenone with phenyl hydra-
zine hydrochloride (Rahaman et al., 2010).The aldol condensation reaction (Nassar, 2010) between 3-
indolaldehyde 279 and 4-methoxyacetophenone 280 afforded
chalcone derivatives 281 which were further reacted with the
cyclizing agents such as hydrazine hydrate and phenyl hydra-
zine to yield pyrazolines 282 and 281 (Scheme 64).
The heterocyclic compounds 286 have been synthesized
(Gupta et al., 2010) starting from the Claisen–Schmidt reac-
tion of aryl methyl ketones 284 and 4-chlorobenzaldehyde 285
to give 286. The reaction of chalcone with phenylhydrazine
in glacial acetic acid using ultrasonic irradiation led to the
formation of 1,3,5-triphenyl-pyrazolines 287 (Scheme 65).
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Synthetic and biological studies of pyrazolines and related heterocyclic compounds 573An efﬁcient and simple procedure has been developed
(Azarifar et al., 2010) for the oxidation of 1,3,5-trisubstituted
4,5-dihydro-1H-pyrazoles 289 and isoxazoles 289 to their
corresponding aromatic derivatives which was promoted by
bis-bromine-1,4-diazabicyclo[2.2.2]octane complex (DABCO-
Br2) in acetic acid at room temperature (Scheme 66).
1-Benzimidazolyl-3-aryl-prop-2-ene-1-ones 291 have been
transformed into N1-substituted pyrazoline derivatives
(Rajora et al., 2010) by reacting with phenyl hydrazine,
hydrazine hydrate in the presence of formic acid under
solvent free microwave induced protocol to give 292 and 293
respectively while the reaction of 291 with thiosemicarbazide
under anhyd. K2CO3 could provide 294 (Scheme 67).
The chalcones 297 and 300 were released (Babu et al., 2007)
starting from 2-acetyl benzofuran 295 and further condensedwith different aromatic acid hydrazides to give the
corresponding pyrazolines 298 and 301 (Scheme 68).
Pawan K. Sharma and co-workers (Sharma et al., 2010)
have reported the synthesis of new pyrazolylpyrazolines 306.
These compounds were obtained by the reaction of appropri-
ate chalcones 304 with 4-hydrazinobenzenesulfonamide
hydrochloride in alcoholic medium (Scheme 69).
The pyrazoline compounds 309 and their 1-acetylated
derivatives (Congiu et al., 2010), bearing a 3,4,5-trimethoxy-
phenyl moiety combined with a variety of substituted phenyl
rings were obtained according to the reaction sequence as
shown Scheme 70 and these compounds were also evaluated
for antitumor activity. The results of the in vitro assay
against a non-small cell lung carcinoma cell line (NCI-H460)
showed several compounds to be endowed with cytotoxicity
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574 M. Yusuf, P. Jainin micromolar to submicromolar range, depending on the
substitution pattern and position of aryl rings on 4,5-
dihydropyrazole core. Potent and selective activity was also
observed in the NCI 60 human cancer cell line panel.
An efﬁcient preparation of compounds 314 has been
reported with the objective of discovering the novel (Scheme
71) and potent anti-inﬂammatory agent (Chandra et al.,
2010). The compound 1-(20,40-Chloroacridine-90-yl)-3-(50-pyridine-4-yl)-(1,3,4-oxadiazol-2-ylthiomethyl)-pyrazole-5-one
314 showed better anti-inﬂammatory and analgesic activities at
the three graded dose of 25, 50 and 100 mg/kg p.o.
A series of 1-acetyl/propyl-3-aryl-5-(5-chloro-3-methyl-1-
phenyl-1H-pyrazol-4-yl)-2-pyrazolines 318 were synthesized
(Girisha et al., 2010) in one step by condensing suitably
substituted propenones 317 with hydrazine in the presence of
acetic/propionic acid (Scheme 72).
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Synthetic and biological studies of pyrazolines and related heterocyclic compounds 575The reaction of 2-cyano-N-(9,10-dioxo-9,10-dihydro-
anthracen-2-yl)-acetamide 320 with phenyl isothiocyanate/dimethylsulphate afforded (Gouda et al., 2010) the
corresponding ketene N,S-acetal 322 which upon treatment
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576 M. Yusuf, P. Jainwith hydrazine hydrate and 4-aminoantipyrine resulted in the
formation of pyrazole derivatives 323 and 324 respectively
(Scheme 73).
The treatment (Abu-Surrah et al., 2010) of 5-hydrazino-1,3-
dimethyl-4-nitro-1H-pyrazole 325 with substituted benzalde-
hydes 326 in methanol gave new substituted Schiff base
ligands 327 (Scheme 74).Recently, synthesis and pharmacological evaluation of a
new class of human carbonic anhydrase (hCA) inhibitors,
1,5-diarylpyrrole-3-carboxamides 331 have been reported
(Gluszok et al., 2010) and these derivatives were prepared by
a solid-phase strategy involving a PS(HOBt) resin (Scheme 75).
A series of novel 5-aryl-1-arylthiazolyl-3-ferrocenyl-pyrazo-
line derivatives 335 have been synthesized (Liu et al., 2010) by
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578 M. Yusuf, P. Jainthe reaction of ferrocenyl chalcone 383 and thiosemicarbazide
followed by the reaction with 2-bromo-1-arylethanone in
48–90% yields (Scheme 76).
To ﬁnd structural requirements for more active antiamoe-
bic agents than metronidazole, the synthesis and comparativeN
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thiocarbamoyl-3-phenyl-2-pyrazolines 335a (Adhikari et al.,
2010). The best model was obtained by using PLS technique
with R2A and R2CV value of 88.50% and 82.90%,
respectively. Amoebicidal activity may increase when Wang–
Ford charges at atom numbers 6 and 12 have large positive
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Synthetic and biological studies of pyrazolines and related heterocyclic compounds 579The reaction of 336 with primary amine leads to the forma-
tion of pyrrole (Xue et al., 2010) while similar treatment of
336 with secondary amine provides 337 and 338 (Scheme 77).
A convenient synthesis (Krishna and Prapurna, 2010) of
pyrazolines 341 is reported via DABCO mediated reaction of
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584 M. Yusuf, P. Jainethyl diazoacetate (EDA) with Baylis–Hillman acetates
(Scheme 78). Here the products were obtained in good to
excellent yields (70–95%).A series of N-substituted-3-[(20hydroxy-40prenyloxy)-phe-
nyl]-5-phenyl-4,5-dihydro-(1H)-pyrazolines 346 and 347 were
synthesized (Scheme 79) and tested on human monoamine oxi-
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Synthetic and biological studies of pyrazolines and related heterocyclic compounds 585dase-A and -B isoforms (Fioravanti et al., 2010). The structure
activity relationships and molecular modeling showed that
some substituents, such as benzyloxy or chlorine, improve
the best interaction with active site of hMAO-B.
Iodocyclization of 5-amino-1-(2,4-dinitrophenyl)-1H-4-pyr-
azolcarboxamides 349 with aromatic aldehydes 350 gave a newseries of pyrazolo[3,4-d]pyrimidine derivatives 350 in a single
step (Bakavoli et al., 2010) and their antibacterial activity
was found to be comparable to Streptomycin which was
used as a reference drug (Scheme 80).
Bandgar et al. (2010) have described the synthesis of a
combinatorial library of 3,5-diaryl-pyrazole derivatives 352
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586 M. Yusuf, P. Jainusing 8-(2-(hydroxymethyl)-1-methylpyrrolidin-3-yl)-5,7-dime-
thoxy-2-phenyl-4H-chromen-4-one 351 and hydrazine
hydrate in absolute ethanol under the reﬂuxing conditions
(Scheme 81).
Recently, a series of N-alkyl 1-aryl-5-(1H-pyrrol-1-yl)-1H-
pyrazole-3-carboxamides 354 have been synthesized as new
ligands of the human recombinant receptor hCB1 (Silvestri
et al., 2010). n-alkyl carboxamides brought out different
SARs from the branched subgroup (Scheme 82).
The novel 3,4-disubstituted pyrazoles 359 were prepared
(Franchini et al., 2010) according to the reaction sequence as
shown in Scheme 83.
The functionally substituted pyrazole compounds 364
and 365 have been prepared (Nitulescu et al., 2010) and
evaluated in vitro for their antiproliferative effects on a
panel of 60 cellular lines, according to the National
Cancer Institute screening protocol (Scheme 84). Three of
the 12 tested compounds showed moderate antitumor
activity, one of them being chosen for the 5-dose assay
and presented logGI50 values up to 5.75.
The new compound 3-[(E)-3-(dimethylamino)acryloyl]-1,5-
diphenyl-1H-pyrazole-4-carbonitrile 369 was prepared (Faraget al., 2010) via the reaction of 3-acetyl-1,5-diphenyl-1H-
pyrazole-4-carbonitrile 366 with dimethylformamid-
dimethylacetal (DMF-DMA) (Scheme 85). The heterocyclic
compound 374 has been obtained starting from 370 via
various steps as shown in Scheme 86.
The novel dipyrazole ethandiamide compound of pyrazol-
o[3,4-d]pyrimidine 4(5H)-one 377 was synthesized (Youssef
et al., 2010) and reacted with a number of nucleophiles
to yield 378. These compounds were tested in several
in vitro and in vivo assays (Scheme 87). Two compounds
were notable for their anti-inﬂammatory activity that
was comparable to that of the clinically available
cyclooxygenase-2 inhibitor celecoxib. Modeling studies by
using the molecular operating environment module showed
comparable docking scores for the two enantiomers docked
in the active site of cyclooxygenase-2.
A series of potential anti-oxidant and anti-bacterial N0-aryl-
methylidene-2-(3,4-dimethyl-5,5-dioxidopyrazolo[4,3-c][1,2]
benzothiazin-2(4H)-yl)acetohydrazides 383 were synthesized
(Ahmad et al., 2010) in a facile way starting from
commercially available saccharine. The various steps
involved in these syntheses are shown in Scheme 88.
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Synthetic and biological studies of pyrazolines and related heterocyclic compounds 587Pyrazole carboxylic acid derivatives (Kasimogullari et al.,
2010) of 5-amino-1,3,4-thiadiazole-2-sulfonamide (inhibitor
1) 385 were obtained from ethyl 3-(chlorocarbonyl)-1-(3-nitro-
phenyl)-5-phenyl-1H-pyrazole-4-carboxylate compound (Scheme
89).
Regioselective 1,3-dipolar cycloaddition of nitrilimines with
5-arylidene-2-arylimino-4-thiazolidinones and with 2-(4-ary-
lidene)thiazolo[3,2-a]benzimidazol-3(2H)-ones 386 afforded
(Abdel-Aziz et al., 2010) the corresponding 1,3,4-triaryl-5-N-
arylpyrazole-carboxamides 388 and pyrazolylbenzimidazoles
389 (Scheme 90).
Adam A. Bekhit et al. (2010) have reported the synthesis of
a novel series of 4-thiazolylpyrazolyl derivatives 400 according
to the reaction sequence as given in Scheme 91. All the newly
synthesized compounds were examined for their anti-inﬂammatory activity using cotton pellet-induced granuloma
and carrageenan-induced rat paw edema bioassays. Their
inhibitory activities of cyclooxygenase-1 and cyclooxygenase-
2 (COX-1 and COX-2), ulcerogenic effect and acute toxicity
were also determined.
The heterocyclic compounds (E)-1-aryl-3-(3-aryl-1-phenyl-
1H-pyrazol-4-yl)prop-2-en-1-ones 405 (pyrazolic chalcones)
were synthesized (Insuasty et al., 2010) from a Claisen–
Schmidt reaction of 3-aryl-1-phenylpyrazol-4-carboxaldehydes
404 with several acetophenone derivatives. Subsequently, the
microwave-assisted cyclocondensation reaction of chalcones
405 with hydrazine afforded the new racemic 3-aryl-4-(3-aryl-
4,5-dihydro-1H-pyrazol-5-yl)-1-phenyl-1H-pyrazoles 405 a or
their N-acetyl derivatives 405 b when the reactions were
carried out in DMF or acetic acid, respectively (Scheme 92).
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588 M. Yusuf, P. Jain1-(30-(9H-carbazol-4-yloxy)-20-hydroxypropyl)-3-aryl-1H-
pyrazole-5-carboxylic acid derivatives 408 have been prepared
(Nagarapu et al., 2010) by the reaction of ethyl 3-aryl-1H-
pyrazole-5-carboxylate 406 with 4-oxiranylmethoxy-9H-
carbazole 407 in moderate to excellent yields (Scheme 93).
The cytotoxicity of synthesized compounds was evaluated by
a SRB (sulforhodamine B) assay against cancer cells such as
SK-N-SH human neuroblastoma (NB), human A549 lung
carcinoma, human breast cancer MCF-7 cell lines. The
results showed that seven compounds can suppress SK-N-SH
tumor cancer cell growth.
Two series of pyrazole derivatives 411 and 412 (Lv et al.,
2010) designing for potential EGFR kinase inhibitors have
been investigated (Scheme 94). Some of them exhibited signi-
ﬁcant EGFR inhibitory activity. The compound 3-(3,4-dimeth-
ylphenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole-1-car
bothioamide 411 (C5) displayed the most potent EGFR
inhibitory activity with IC50 of 0.07 lM, which was
comparable to the positive control erlotinib.A number of biologically signiﬁcant conjugates were syn-
thesized by the combination of chromone-pyrimidine, chro-
mone-indolinone, chromone-pyrazole, indole-pyrimidine,
indole-indolinone and indole-pyrazole moieties (Singh et al.,
2010) according to the method which is described in Scheme
95.
Recently, Serkos A. Haroutounian et al. (Christodoulou et
al., 2010) have investigated the synthesis of a series of novel
trisubstituted pyrazole derivatives 421 and these compounds
have also been PIFA-mediated converted to molecules bearing
the fused pyrazolo[4,3-c]quinoline ring. The various steps
involved in these syntheses have been described in Schemes 96.
New 1-N-substituted-3,5-diphenyl-2-pyrazoline derivatives
430 have been synthesized (Scheme 97) and their cyclooxygen-
ase (COX-1 and COX-2) inhibitory activities have also been
evaluated (Fioravanti et al., 2010). The results of these biolog-
ical assays showed that all the new derivatives are not endowed
with improved anti-inﬂammatory activity against COX-1,
but some of them showed a good activity against COX-2.
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Synthetic and biological studies of pyrazolines and related heterocyclic compounds 589The compounds 439 have been released (Velankar et al.,
2010) starting from benzyl nitrile 431 through the multistep
reactions and their conditions have been depicted in Scheme
98. The synthesized compounds showed interleukin-2 inducible
T-cell kinase (ITK) which is one of the ﬁve kinases that
belong to the Tec kinase family and it plays an important role
in T-cell and mast cell signaling. Various reports point to a
role of ITK in the treatment of allergic asthma.
The synthesis of a series of pyrazoles 443 has been reported
(Scheme 99) and these heterocyclics were also evaluated for
their PDE4 inhibitory activity (Biagini et al., 2010). All the
pyrazoles were found devoid of activity, whereas some of the
pyrazolo[3,4-d]pyridazinones showed good activity as PDE4
inhibitors.3,5-Diaryl-1H-pyrazoles 446 were prepared (Shaw et al.,
2010) from the cyclization of 1,3-diketone 446 with
hydrazine hydrochloride (Scheme 100). The major interest in
the study was to obtain a molecular template which may act
as growth-inhibitory agents.
The cyclization of chalcones 450 with 2-(quinolin-8-yloxy)
acetohydrazide 451 under basic condition (Hayat et al.,
2010) led to the formation of new pyrazoline derivatives 452
(Scheme 101).
In order to ﬁnd a new class of antimicrobial agents
(Bondock et al., 2010), a series of pyrazole 460 and 462 and
other related products 458 containing benzothiazole moiety
have been reported by Samir Bondock et al. according to the
detailed protocol which is given in Scheme 102.
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590 M. Yusuf, P. JainNovel 1,5-diaryl pyrazole derivatives 466 and 467 were syn-
thesized (Ragavan et al., 2010) from the condensation of 464
with phenyl hydrazine in alcoholic medium (Scheme 103).
An effective and solvent free method for the synthesis
(Kumar et al., 2011) of pyrazole-substituted chalcones 470
has been achieved by grinding pyrazole aldehydes 468 and
acetophenones 469 in the presence of activated bariumhydroxide (C-200). The products of these reactions have
been obtained in high yield and within short span of
time (Scheme 104).
A series of new 1,3,5-trisubstituted-2-pyrazolines
473 were prepared (Srinath et al., 2011) by reacting
chalcones 471 with phenylhydrazine hydrochloride 472
(Scheme 105).
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sized (Dadiboyena and Hamme, 2011) through a tandem
intramolecular cyclization/methylation reaction of a functio-
nalized 5,5-disubstituted pyrazoline in one reaction vessel
(Scheme 106).1,3,5-Trisubstituted pyrazolines 481 are rapidly and conve-
niently oxidized (Azarifar et al., 2011) to their corresponding
pyrazoles 483 by 1,3-dichloro-5,5-dimethylhydantoin (DCH)
in solution and solvent-free conditions under microwave
irradiation (Scheme 107). The presence of silica gel as a
OO
CHO
R
2
R
1
+ N
N
COOR
3
COOR
3 + PPh3
O
O
R
2
R
1
N
N COOR
3
COOR
3
+
O
O
R
2
R
1
N
N
N
N
COOR
3
COOR
3
COOR
3
COOR
3
toluene, reflux
R1 = H, Me, i-Pr, Cl
R2 = H, Me
R3 = i-Pr, Et
485
486 487
488
Scheme 108
O
H
R
3
R
2 R
1
+
O
CH3
R
4
R
3
R
2 R
1 O
R
4
R
3
R
2 R
1
CH2
N
R
4
N
R
O
NaOH/ EtOH/ SOCl2/ EtOH
NH2NH2/ AcOHNH2NH2/ HCOOH
489 490
491
492
Scheme 109
N N
R
2R
1
Ph
+
N
N
O
Cl
Cl
CH3
CH3
O
N N
R
2R
1
Ph
+
N
H
N
H
O
CH3
CH3
O
MW/ AcOH or solvent free
481 482 483 484
Scheme 107
594 M. Yusuf, P. Jainsupporting agent is shown to be effective in reducing the
reaction times and increasing the yields.
The zwitterionic intermediates generated from dialkyl azo-
dicarboxylates and triphenylphosphine displayed excellent
reactivity (Papaﬁlippou et al., 2011) toward 3-formylchro-
mones to afford chromeno[2,3-c]pyrazolines 487 and chro-
meno[2,3-e]tetrazepines 488 (Scheme 108).
A series of 2-pyrazolines 492 have been synthesized (Panta
et al., 2011) from a,b unsaturated ketones 491 and hydrazine
hydrate with acetic/formic acid in ethanol/DMSO as shown
in Scheme 109.Acknowledgment
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